Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oracure is a topical oral gel used for the symptomatic relief of painful inflammatory conditions of the mouth, including oral mucositis, mouth ulcers, and gingivitis. It is a combination product typically formulated with an analgesic and anti-inflammatory agent (choline salicylate), a local anesthetic (lidocaine), and an antiseptic (benzalkonium chloride). Choline salicylate provides relief from pain and inflammation by inhibiting cyclooxygenase enzymes, while lidocaine offers rapid local anesthesia by blocking voltage-gated sodium channels. Benzalkonium chloride acts as a broad-spectrum antiseptic to prevent secondary microbial infections in damaged oral mucosa. In clinical research, Oracure has been utilized as a component of conventional symptomatic treatment regimens for managing radiation-induced oral mucositis in patients with head and neck cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oracure (Amoun Pharmaceutical).